drugset / Trial / NCT04953923
Thorough QT Assessment of Cedazuridine in Healthy Subjects
RandomizedCrossoverQuadruple-blindBasic science
Summary
This study is designed to evaluate the effect of therapeutic and supratherapeutic oral doses of cedazuridine on cardiac repolarization, as detected by QTc in healthy subjects, in accordance with regulatory guidelines. Moxifloxacin will be used to validate the study. Study duration per participant is approximately 20 days.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2021-11-15
- Completion
- 2021-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cedazuridine | Small molecule | — | Oral |
| Comparator | Moxifloxacin | Small molecule | — | Oral |
Indications
No indication recorded.